NCCM
JUNO

Nine Chapters Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Nine Chapters Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-7,500
Closed -$400K – 1293
2015
Q2 		$400K Buy
+7,500
New +$398K 0.03% 643

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM

Nine Chapters Capital Management's JUNO Position: Q3 2015 in Review

Nine Chapters Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2015, closing a stake of 7,500 shares — an estimated $400K sold.

Nine Chapters Capital Management first reported a position in JUNO in Q2 2015 and held it in 1 quarter. The position peaked at $400K in Q2 2015. 132 funds tracked by Wall St. Rank hold JUNO as of Q3 2015.

  • Nine Chapters Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Nine Chapters Capital Management sold 7,500 Juno Therapeutics, Inc. shares in Q3 2015, an estimated $400K.
  • Nine Chapters Capital Management first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • Nine Chapters Capital Management's Juno Therapeutics, Inc. position peaked at $400K in Q2 2015.
  • 132 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2015.

Based on Nine Chapters Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.